#42USNASDAQ

INCY

Incyte

$117.39USD

Data as of 2026-07-21

Composite Score67.1Strong

−9

Margin of safety−9%Fair value

Fair value$107.86

Target$169.15

Loss chance35%Moderate-low

SizeLarge cap

SectorHealth Care

Dividend—

TypeCommon stock

Price

Pillar breakdown

0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)

Health Care median (n=166)

Quality
Profit margins & asset efficiency
73
Exceptional
Health Care median (n=166) 50
Value
Price vs fundamentals
46
Average
Health Care median (n=166) 52
Growth
Revenue & earnings trajectory
77
Exceptional
Health Care median (n=166) 50
Momentum
Recent price strength
63
Strong
Health Care median (n=166) 49
Health
Balance sheet & solvency
77
Exceptional
Health Care median (n=166) 57
Profitability
ROE, ROA, ROIC
89
Exceptional
Health Care median (n=166) 48
Technical
Trend & volatility signals
61
Strong
Health Care median (n=166) 56
Risk
Volatility & drawdown profile
74
Exceptional
Health Care median (n=166) 46

025405570100

Exceptional (70+)Strong (55–70)Average (40–55)Weak (25–40)Poor (<25)

Pillars not shown: Sentiment, ML (Phase 5+).

Risk Summary

Low

Manipulation index

5/100

Composite penalty: −0.50 pts (informational; rank uses raw composite)

Fired components (2)

Restatement history (10-K/A, 5y)[restatement_history]
Accruals momentum (Δ TATA > 0.05 over 3y)[accruals_momentum_high]

Rolls up Phase 4.5 earnings-manipulation defenses (Sloan · Beneish · Dechow · REM · restatement · late-filing · earnings- quality time-series) into a single 0-100 risk index. The soft composite penalty (max 10 pts) is informational only — the ranking uses the raw composite score per project Rule 16.

Fair price check

5 different valuation methods each estimate what INCYshould be worth, then we compare to today's price.

Near fair value

Models suggest INCY is priced roughly in line

Today's price

$117.39

Median fair price

$107.86

-8% vs today's price

Of 5 methods:2 say cheap1 say fair2 say pricey

P/E multiplesUndervalued
thinks it's a bargain — estimates $169.15, about 44% above today
P/B multiplesUndervalued
thinks it's a bargain — estimates $148.71, about 27% above today
EV/EBITDAFair
thinks it's fairly priced — estimates $107.86, about 8% below today
Graham (defensive)Overvalued
thinks it's expensive — estimates $42.62, about 64% below today
Residual IncomeOvervalued
thinks it's expensive — estimates $28.70, about 76% below today

How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.

Fair price ensemble

Median fair: $107.86
Margin of safety(vs fair value): -8.8%
Max (ex-outliers): $169.15
Tangible BVPS: $26.29

Restatement history
Accruals momentum

Median of all applicable methods (current price $117.39). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.

Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.

Supporting dataRaw fundamentals & data-quality provenance behind the scores above

Raw fundamentals (SEC EDGAR)

Metric	Value
Market cap	$23.45B
Revenue (TTM)	$5.36B
Net income (TTM)	$1.43B
Operating cash flow (TTM)	$1.52B
CapEx (TTM)	$77.83M
Free cash flow (TTM)CFO − CapEx	$1.44B
Total assets	$7.34B
Total liabilities	$1.72B
Stockholders' equity	$5.62B
Cash & equivalents	$3.46B
Shares outstanding	199.78M
EPS (basic)	$7.17
EPS (diluted)	$7.17
P/E ratio (TTM)	16.38

TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).

Data quality

Latest filed date: 2026-04-28
Latest period end: 2026-04-21
Filing lag: 84 days
Missing metrics: 3(gross_profit, dividends_paid, accounts_receivable)